http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108414660-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8822 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 |
| filingDate | 2018-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108414660-B |
| titleOfInvention | Application of group of plasma metabolism small molecule markers related to early diagnosis of lung cancer |
| abstract | The invention discloses a group of plasma metabolism small molecular markers related to early diagnosis of lung cancer and application thereof, wherein the plasma metabolism small molecular markers comprise one or more of the following markers: propionic acid, aspartic acid, furanoside, citric acid, allose, talose, galactopyranose, pyruvic acid, tryptophan, leucylproline, glycerophosphorylcholine, oleoylcarnitine, lysophosphatidylcholine (18: 3), lysophosphatidylcholine (18: 2), lysophosphatidylcholine (18: 1), lysophosphatidylcholine (22: 6), lysophosphatidylethanolamine (20: 0), lysophosphatidylethanolamine (18: 2), and lacylvaline. Compared with the traditional protein biomarkers, the group of markers provided by the invention has stronger association with the fate of the disease, is stable, minimally invasive and easy to detect, greatly improves the sensitivity and specificity of diagnosis of related diseases, and is suitable for early clinical diagnosis and monitoring of lung cancer. |
| priorityDate | 2018-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 53.